Company Encyclopedia
View More
name
CYCLACEL PHARMACEUTICALS INC 6% CNV PFD USD
CYCCP.US
News
View More

CYCLACEL PHARMACEUTICALS INC 6% CNV PFD USD | 10-Q: FY2025 Q2 Revenue: USD 0

LB filings·
US
CYCCP
0.00%
US
BGMSP
-9.64%
LB filings·
US
CYCCP
0.00%
US
BGMSP
-9.64%

CYCLACEL PHARMACEUTICALS INC 6% CNV PFD USD | 8-K: FY2025 Q2 Revenue: USD 0

LB filings·
US
CYCCP
0.00%
US
BGMSP
-9.64%
LB filings·
US
CYCCP
0.00%
US
BGMSP
-9.64%

CYCLACEL PHARMACEUTICALS INC 6% CNV PFD USD | 8-K: FY2025 Q1 Revenue: USD 0

LB filings·
US
CYCCP
0.00%
US
BGMSP
-9.64%
LB filings·
US
CYCCP
0.00%
US
BGMSP
-9.64%

CYCLACEL PHARMACEUTICALS INC 6% CNV PFD USD | 10-Q: FY2025 Q1 Revenue: USD 0

LB filings·
US
CYCCP
0.00%
US
BGMSP
-9.64%
LB filings·
US
CYCCP
0.00%
US
BGMSP
-9.64%

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

KUALA LUMPUR, Malaysia, March 24, 2025 ( GLOBE NEWSWIRE ) -- Cyclacel Pharmaceuticals, Inc. ( "Cyclacel" ) ( NASDAQ: CYCC, NASDAQ: CYCCP ) , a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities purchase agreement for the sale ...

GlobeNewswire·
US
CYCC
0.00%
US
CYCCP
0.00%
US
BGMS
+7.69%
GlobeNewswire·
US
CYCC
0.00%
US
CYCCP
0.00%
US
BGMS
+7.69%
© 2025 Longbridge｜Disclaimer